Ocular neuromyotonia secondary to a cavernous sinus meningioma.
Jacob
Maud
M
Unité de Neuro-Ophtalmologie, Hôpital Neurologique, Hospices Civils de Lyon, Université Claude Bernard Lyon I, Bron, France.
Vighetto
Alain
A
Bernard
Martine
M
Tilikete
Caroline
C
D000086:Acetazolamide / Q000627:therapeutic use; D000328:Adult; D002220:Carbamazepine / Q000031:analogs & derivatives / Q000627:therapeutic use; D002426:Cavernous Sinus / Q000473:pathology*; D002998:Clonazepam / Q000627:therapeutic use; D004172:Diplopia / Q000188:drug therapy / Q000209:etiology; D004948:Esotropia / Q000209:etiology*; D005260:Female; D006801:Humans; D020386:Isaacs Syndrome / Q000188:drug therapy / Q000209:etiology*; D008577:Meningeal Neoplasms / Q000150:complications* / Q000175:diagnosis / Q000473:pathology; D008579:Meningioma / Q000150:complications* / Q000175:diagnosis / Q000473:pathology; D009408:Nerve Compression Syndromes / Q000209:etiology*; D015840:Oculomotor Nerve Diseases / Q000188:drug therapy / Q000209:etiology*; D000078330:Oxcarbazepine; D014277:Trigeminal Neuralgia / Q000209:etiology
D002220:Carbamazepine; D002998:Clonazepam; D000086:Acetazolamide; D000078330:Oxcarbazepine